


FENDIGO SA
Balance Sheet as at 31 March, 2019
Amounts in Euros (€) unless otherwise stated

Particulars	Note No.	As at 31 Mar 2019	As at 31 Mar 2018
ASSETS			
1 Non-current assets			
(a) Property, plant and equipment	3	4,569	8,692
(b) Financial assets			
(i) Others financial assets	4	112	112
		4,681	8,804
2 Current assets			
(a) Inventories	5	18,19,463	18,49,045
(b) Financial Assets			
(i) Trade receivables	6	7,77,705	7,62,556
(ii) Cash and cash equivalents	7	6,11,412	95,448
(iii) Loans	8	5,12,275	5,09,940
(iv) Other financial assets	9	3,317	5,488
(c) Other current assets	10	21,210	17,367
		37,45,382	32,39,844
TOTAL ASSETS		37,50,063	32,48,648
EQUITY AND LIABILITIES			
1 Equity			
(a) Equity share capital	11	1,54,933	1,54,933
(b) Other equity	12		
(i) Retained earnings		6,40,053	4,55,598
(ii) Other reserves		4,30,914	4,30,914
		12,25,900	10,41,445
2 Current liabilities			
(a) Financial liabilities			
(i) Short-term borrowings	13	4,50,000	5,75,000
(ii) Trade payables	14	18,84,027	15,86,962
(b) Other current liabilities	15	12,136	14,054
(c) Current tax liabilities (Net)	16	1,78,000	31,187
		25,24,163	22,07,203
TOTAL EQUITY AND LIABILITIES		37,50,063	32,48,648

See accompanying notes to the financial statements


As per our report of event date
For M O J & ASSOCIATES
Chartered Accountants
ICAI FRN: 015425S


Avneep Mehta
Partner
Membership no. 225441



Place: Bengaluru
Date: **May 13, 2019**

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS


Ashish Kakabalia
Director



Place: Thane
Date: **May 13, 2019**

FENDIGO SA**Statement of Profit and Loss for the year ended 31 March, 2019**

Amounts in Euros (€) unless otherwise stated

Particulars	Note No	Year ended 31 Mar 2019	Year ended 31 Mar 2018
1 Revenue From Operations	17	79,16,416	75,26,422
2 Other Income	18	14,904	23,349
3 Total Income (1+ 2)		79,31,321	75,49,771
4 EXPENSES			
Purchases of stock-in-trade	19	47,09,822	48,80,975
Changes in inventories of finished goods and work-in-progress & intermediates	20	29,582	(6,31,685)
Employee benefits expense	21	8,01,186	8,19,441
Finance costs	22	18,391	18,343
Depreciation and amortization expense	23	4,123	6,789
Other expenses	24	18,05,762	19,54,896
Total expenses (4)		73,68,865	70,48,760
5 Profit before tax (3- 4)		5,62,455	5,01,011
6 Tax expense:	25		
Current tax		1,78,000	1,80,887
7 Profit (Loss) for the year (5-6)		3,84,455	3,20,124
8 Other Comprehensive Income		-	-
9 Total Comprehensive Income for the period (7+ 8)		3,84,455	3,20,124
10 Earnings per equity share:	27		
(1) Basic		61.51	51.22
(2) Diluted		61.51	51.22

See accompanying notes to the financial statements

As per our report of event date


For M O J & ASSOCIATES**Chartered Accountants**

ICAI FRN: 015425S

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS

**Avneep Mehta
Partner**

Membership no. 225441



**Ashish Kakabalia
Director**

Place: Bengaluru

Date: May 13, 2019

Place: Thane

Date: May 13, 2019

FENDIGO SA


Statement of cash flows for the year ended 31 March, 2019

Amounts in Euros (€) unless otherwise stated

	Year ended 31 Mar 2019	Year ended 31 Mar 2018
Cash flow from operating activities		
Net Profit before tax	5,62,455	5,01,011
Adjustments for:		
Depreciation and amortisation expense	4,123	6,789
Finance cost	18,391	18,343
Interest income	(12,743)	(13,362)
Operating profit before working capital changes	5,72,226	5,12,781
Changes in working capital		
(Increase)/decrease in trade receivables	(21,327)	(1,85,854)
(Increase)/decrease in inventories	29,582	(6,31,685)
Increase/(decrease) in trade and other payables	2,95,147	5,50,535
Net change in working capital	3,03,402	(2,67,004)
Cash generated from operations	8,75,628	2,45,777
Direct taxes (paid)/refund	(31,187)	(3,03,275)
Net cash generated from operating activities	8,44,441	(57,498)
	A	
Cash flow from investing activities		
Capital expenditure on fixed assets	-	(6,066)
Interest received	14,914	5,170
Net cash generated from investing activities	14,914	(896)
	B	
Cash flow from financing activities		
Proceeds/(Repayment) from/of short term borrowings (net)	(1,25,000)	1,00,000
Finance cost	(18,391)	(18,343)
Dividend paid	(2,00,000)	(4,00,000)
Net cash generated from financing activities	(3,43,391)	(3,18,343)
	C	
Net increase/(decrease) in cash and cash equivalents during the year/ period	5,15,964	(3,76,737)
	A+B+C)	
Cash and cash equivalents at the beginning of the year	95,448	4,72,185
Cash and cash equivalents at the end of the year	6,11,412	95,448
Reconciliation of cash and cash equivalents with the Balance sheet		
Cash on hand	301	16
Balances with banks	6,11,111	95,432
Cash and cash equivalents as per Balance Sheet (Refer Note 7)	6,11,412	95,448

See accompanying notes to the financial statements


As per our report of event date
For M O J & ASSOCIATES
Chartered Accountants
 ICAI FRN: 015425S


Avneep Mehta
Partner
 Membership no. 225441



Place: Bengaluru
 Date: **May 13, 2019**

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS


Ashish Kakabalia
Director



Place: Thane
 Date: **May 13, 2019**

FENDIGO SA**Statement of Changes in Equity (SOCIE) for the year ended 31 March, 2019**

Amounts in Euros (€) unless otherwise stated

(a) Equity share capital

	As at 31 Mar 2019		As at 31 Mar 2018	
	No. of Shares	Amount	No. of Shares	Amount
Balance at the beginning of the reporting year	6,250	1,54,933	6,250	1,54,933
Changes in equity share capital during the year	-	-	-	-
Balance at the end of the reporting year	6,250	1,54,933	6,250	1,54,933

(b) Other Equity

Particulars	Reserves and Surplus		Total
	General reserve	Retained Earnings	
Balance at April 1, 2017	4,30,914	5,35,474	9,66,388
Profit for the year	-	3,20,124	3,20,124
Payment of Dividends	-	(4,00,000)	(4,00,000)
Balance at March 31, 2018	4,30,914	4,55,598	8,86,512
Profit for the year	-	3,84,455	3,84,455
Payment of Dividends	-	(2,00,000)	(2,00,000)
Balance at March 31, 2019	4,30,914	6,40,053	10,70,967

See accompanying notes to the financial statements

As per our report of event date

For M O J & ASSOCIATES

Chartered Accountants


ICAI FRN: 015425S

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS

Avneep Mehta

Partner

Membership no. 225441



Ashish Kakabalia

Director



Place: Bengaluru

Date: May 13, 2019

Place: Thane

Date: May 13, 2019

Fendigo SA
Notes forming part of the financial statements for the year ended 31 March, 2019

Note

1 Legal status and principal activities

Fendigo SA ("the Company") is a company incorporated in Brussels (Belgium) in 1995 and is engaged in the distribution of veterinary pharmaceuticals and animal health products in Benelux region (Belgium, Netherlands and Luxembuorg).

2 Significant accounting policies

2.1 Basis of accounting and preparation of financial statements

The Financial Statements have been prepared on accrual basis under the historical cost convention except for certain categories of fixed assets that are carried at revalued amounts.

The financial statements of Fendigo SA ('the Company') have been prepared, in accordance with Indian Accounting Standards ("Ind AS") notified under the Companies (Indian Accounting Standards) Rules, 2015.

2.2 Tangible fixed assets

Fixed assets are carried at cost less accumulated depreciation and impairment losses, if any. The cost of fixed assets comprise its purchase price net of any trade discounts and rebates, any import duties and other taxes (other than the subsequently recoverable from the tax authorities), any directly attributable expenditure on making the asset ready for its intended use, other incidental expenses and interest on borrowings attributable to acquisition of qualifying fixed assets to the date the asset is ready for its intended use. Exchange differences arising on restatement/settlement of long-term foreign currency borrowings relating to acquisition of depreciable fixed assets are adjusted to the cost of the respective assets and depreciated over the remaining useful life of such assets. Subsequent expenditure relating to fixed assets is capitalised only if such expenditure results in an increase in the future benefits from such asset beyond its previously assessed standard of performance.

2.3 Depreciation

Depreciation is provided under the straight-line method based on the useful lives:


Nature of Asset	Useful life in periods (range)
Computers	3
Vehicles	1 to 5

2.4 Inventory

Inventories comprises of finished goods. These are valued at the lower of cost and net realizable value. Cost is determined on First in First out basis for finished goods - 'At material cost, conversion costs and an appropriate share of production overheads.

2.5 Revenue recognition

Effective 01 April 2018, the Company adopted IND AS 115, 'Revenue from Contracts with Customers' using the modified retrospective method. In accordance with this, the comparatives have not been retrospectively adjusted and no material impact was recognised.



a) Sale of products

Revenue from sale of products is presented in the income statement within Revenue from operations. The Company presents revenue net of indirect taxes in its statement of profit and loss. Sale of products comprise revenue from sales of products, net of sales returns, rebates, incentives and customer discounts.

Revenue is recognized when it is probable that future economic benefits will flow to the Company and these benefits can be measured reliably. Further, revenue recognition requires that all significant risks and rewards of ownership of the goods included in the transaction have been transferred to the buyer, and that Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold. Performance obligations are satisfied at one point in time, typically on delivery. Revenue is recognized when the Company transfers control over the product to the customers; control of a product refers to the ability to direct the use of, and obtain substantially all of the remaining benefits from, that asset. The majority of revenue earned by the Company is derived from the satisfaction of a single performance obligation for each contract which is the sale of products.

Sales are measured at the fair value of consideration received or receivable. The amounts of rebates/incentives based on attainment of sales targets is estimated and accrued on each of the underlying sales transactions recognised. Returns and customer discounts, as described above, are recognized in the period in which the underlying sales are recognized. The amount of sales returns is calculated on the basis of management's best estimate of the amount of product that will ultimately be returned by customers. The amount recognized for returns is estimated on the basis of past experience of sales returns.

b) Interest and dividend income

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable.

Dividend income from investments is recognised when the Company's right to receive payment has been established.

2.6 Employee benefits

Short term employee benefits are accrued based on the terms of employment when services are rendered by the employees and charged as an expense to the statement of profit and loss.

Leave balances standing to the credit of the employees that are expected to be availed in the short term are provided for on full cost basis.

2.7 Foreign currency transactions

Initial recognition

Transactions in foreign currencies entered into by the Company are accounted at the exchange rates prevailing on the date of the transaction or at rates that closely approximate the rate at the date of the transaction.

Measurement at the Balance Sheet date

Foreign currency monetary items of the Company outstanding at the Balance Sheet date are restated at the period-end rates. Non monetary items of the Company are carried at historical cost. Revenue and expenses are translated at the average exchange rates prevailing during the period.

Treatment of exchange differences

Exchange differences arising on settlement / restatement of foreign currency monetary assets and liabilities of the Company are recognised as income or expense in the statement of profit and loss.

2.8 Taxes on income

Income Tax comprises the current tax provision. Current tax is the amount of tax payable on the taxable income for the period.



2.9 Earnings per share (EPS)

In determining the Earnings per share, the Company considers the net profit after tax. The number of shares used in computing Basic Earnings per share is the weighted average number of equity shares outstanding during the year. The number of shares used in computing Diluted Earnings per share comprises the weighted average number of equity shares considered for deriving Basic earnings per share and also the weighted average number of equity shares that could have been issued on the conversion of all dilutive potential equity shares. Dilutive potential equity shares are deemed converted as of the beginning of the year unless issued at a later date.

2.10 Provisions and contingencies

A provision is recognized when the Company has a present legal or constructive obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which reliable estimate can be made. Provisions (excluding retirement benefits) are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimate. Contingent liabilities are not recognized but are disclosed in the notes to financial statements.

2.11 Use of estimates

The preparation of the financial statements in conformity with the Accounting Standards generally accepted in India requires that the Management makes estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities as at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Management believes that the estimates used in preparation of financial statement are prudent and reasonable. Actual results could differ from those estimates and the estimates are recognised in the period in which the results are known/materialise.

2.12 Segment

Segments have been identified taking into account the nature of operations, the differing risks and returns, the organizational structure and the internal reporting system.

2.13 Insurance claims

Insurance claims are accounted for on the basis of claims admitted / expected to be admitted and to the extent that there is no uncertainty in receiving the claims.

2.13 Borrowing costs

Borrowing costs include interest, amortisation of ancillary costs incurred and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost. Costs in connection with the borrowing of funds to the extent not directly related to the acquisition of qualifying assets are charged to the Statement of Profit and Loss over the tenure of the loan.

2.14 Cash flow statement

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities are segregated based on the available information.

2.14 Cash and cash equivalents (for purposes of cash flow statement)

Cash and cash equivalents in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

2.15 Operating Cycle

Based on the nature of products / activities of the Company and the normal time between acquisition of assets and their realisation in cash or cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.



FENDIGO SA

Notes to the financial statements for the year ended 31 March, 2019

All amounts are in Euros unless otherwise stated

Note 3: Property, Plant and Equipment

	As at 31 Mar 2019	As at 31 Mar 2018
Carrying Amount of:		
Computers	4,569	8,692
Vehicles	-	-
TOTAL	4,569	8,692

	Computers	Vehicles	Total
Cost or deemed cost			
Opening Balance as on 01 April 2017	6,303	4,379	10,682
Additions	6,065	-	6,065
Deletions	-	-	-
Closing Balance as on 31 March 2018	12,368	4,379	16,747
Additions	-	-	-
Deletions	-	-	-
Closing Balance as on 31 March 2019	12,368	4,379	16,747

	Computers	Vehicles	Total
Accumulated depreciation and impairment			
Opening Balance as on 01 April 2017	702	564	1,266
Depreciation / amortisation expense for the year	2,974	3,815	6,789
Deletions	-	-	-
Closing Balance as on 31 March 2018	3,676	4,379	8,055
Depreciation / amortisation expense for the year	4,123	-	4,123
Deletions	-	-	-
Closing Balance as on 31 March 2019	7,799	4,379	12,178

	Computers	Vehicles	Total
Carrying amount			
Opening Balance as on 01 April 2017	5,601	3,815	9,416
Additions	6,065	-	6,065
Deletions	-	-	-
Depreciation expense	2,974	3,815	6,789
Closing Balance as on 31 March 2018	8,692	-	8,692
Additions	-	-	-
Deletions	-	-	-
Depreciation expense	4,123	-	4,123
Closing Balance as on 31 March 2019	4,569	-	4,569



FENDIGO SA

Notes to the financial statements for the year ended 31 March, 2019


Amounts in Euros (€) unless otherwise stated

4	Other non-current financial assets	As at 31 Mar 2019	As at 31 Mar 2018
	Security Deposits	112	112
		112	112
5	Inventories	As at 31 Mar 2019	As at 31 Mar 2018
	Finished goods	18,19,463	18,49,045
		18,19,463	18,49,045
6	Trade receivables	As at 31 Mar 2019	As at 31 Mar 2018
	<u>Unsecured, considered good</u>		
	Trade receivables	7,77,705	7,62,556
		7,77,705	7,62,556
7	Cash and cash equivalents	As at 31 Mar 2019	As at 31 Mar 2018
	Cash on hand	301	16
	Balances with banks		
	- In current accounts	6,11,111	95,432
		6,11,412	95,448
8	Loans	As at 31 Mar 2019	As at 31 Mar 2018
	<u>Unsecured, considered good:</u>		
	Loans & Advances to related parties	5,00,000	5,00,000
	Loans to others	12,275	9,940
		5,12,275	5,09,940
9	Other current financial assets	As at 31 Mar 2019	As at 31 Mar 2018
	Debts due from related parties	3,317	5,488
		3,317	5,488
10	Other current assets	As at 31 Mar 2019	As at 31 Mar 2018
	Prepaid expenses	21,210	17,367
		21,210	17,367
11	Share capital	As at 31 Mar 2019	As at 31 Mar 2018
(a)	Authorised		
	6250 equity shares of EUR 24.79 each	1,54,933	1,54,933
(b)	Issued, Subscribed and fully paid up		
	6250 equity shares of EUR 24.79 each	1,54,933	1,54,933
		1,54,933	1,54,933

Notes:

(i) Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the reporting period:

Particulars	As at 31 Mar 2019		As at 31 Mar 2018	
	No. of shares	Amount	No. of shares	Amount
Equity shares				
Shares outstanding at the beginning of the period	6,250	154,933	6,250	154,933
Add: Shares issued during the period	-	-	-	-
Shares outstanding at the end of the period	6,250	154,933	6,250	154,933



FENDIGO SA

Notes to the financial statements for the year ended 31 March, 2019

Amounts in Euros (€) unless otherwise stated

(ii) Terms/rights attached to equity shares

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts, if any. The distribution will be in proportion to the number of equity shares held by the shareholders.

(iii) Details of shares held by each shareholder holding more than 5% shares**Equity shares**

Name of the shareholder	As at 31 Mar 2019		As at 31 Mar 2018	
	No. of shares	% of Holding	No. of shares	% of Holding
Alivira Animal Health Limited, Ireland, the holding company	5781	92.50%	5,312	85.00%
Mats Carlsson	-	-	469	7.50%
Bernard Bradfer	469	7.50%	469	7.50%

12	Other Equity	As at 31 Mar 2019	As at 31 Mar 2018
(a)	Retained Earnings		
	Opening Balance	4,55,598	5,35,474
	Add: Profit for the year	3,84,455	3,20,124
	Less: Payment of Dividends	(2,00,000)	(4,00,000)
	Closing balance	6,40,053	4,55,598
(b)	Other Reserves - General Reserve	As at 31 Mar 2019	As at 31 Mar 2018
	Securities premium reserve		
	Opening Balance	4,30,914	4,30,914
	Add: Movement during the year	-	-
	Closing balance	4,30,914	4,30,914
	Other Equity (Total) (a+b)	10,70,967	8,86,512
13	Short term borrowings	As at 31 Mar 2019	As at 31 Mar 2018
	Unsecured		
	Loans repayable on demand from banks	4,50,000	5,75,000
		4,50,000	5,75,000
14	Trade Payables	As at 31 Mar 2019	As at 31 Mar 2018
	Trade payable	18,84,027	15,86,962
		18,84,027	15,86,962
15	Other Current Liabilities	As at 31 Mar 2019	As at 31 Mar 2018
	Statutory remittances	12,136	14,054
		12,136	14,054
16	Current tax liabilities (Net)	As at 31 Mar 2019	As at 31 Mar 2018
	Provision for taxation (net off advance tax)	1,78,000	31,187
		1,78,000	31,187



FENDIGO SA
Notes to the financial statements for the year ended 31 March, 2019
Amounts in Euros (€) unless otherwise stated

	Year ended 31 Mar 2019	Year ended 31 Mar 2018
17 Revenue from operations		
Sale of products	79,16,416	75,26,422
	<u>79,16,416</u>	<u>75,26,422</u>
18 Other Income		
Interest income	12,743	13,362
Other non-operating income	2,161	9,987
	<u>14,904</u>	<u>23,349</u>
19 Purchases of stock-in-trade		
Purchases of stock-in-trade	47,09,822	48,80,975
	<u>47,09,822</u>	<u>48,80,975</u>
20 Changes in inventories of finished goods and work-in-progress & intermediates		
Opening stock		
Finished goods	18,49,045	12,17,360
	<u>18,49,045</u>	<u>12,17,360</u>
Closing stock		
Finished goods	18,19,463	18,49,045
	<u>18,19,463</u>	<u>18,49,045</u>
Net (increase) / decrease	<u>29,582</u>	<u>(6,31,685)</u>
21 Employee benefits expense		
Salaries and wages	7,83,592	7,40,738
Contribution to provident and other funds	12,182	72,559
Staff welfare expenses	5,412	6,144
	<u>8,01,186</u>	<u>8,19,441</u>
22 Finance costs		
Interest expense	18,391	18,343
	<u>18,391</u>	<u>18,343</u>
23 Depreciation and amortization expense		
Tangible assets	4,123	6,789
	<u>4,123</u>	<u>6,789</u>
24 Other expenses		
Travel expenses	57,331	70,005
Communication expenses	13,983	14,577
Legal and Professional charges	2,61,211	4,25,371
Freight and forwarding	1,47,294	1,25,497
Rent	37,905	42,666
Repairs to others	2,08,271	2,13,524
Insurance	46,640	68,292
Commission on sales	7,17,437	7,35,294
Advertisement and selling expenses	1,10,770	95,575
Rates and taxes	7,534	11,507
Other expenses	1,97,386	1,52,589
	<u>18,05,762</u>	<u>19,54,896</u>
25 Tax expense		
Current tax	1,78,000	1,80,887
	<u>1,78,000</u>	<u>1,80,887</u>



FENDIGO SA

Notes to the financial statements for the year ended 31 March, 2019

Amounts in Euros (€) unless otherwise stated

26 Related Party Disclosures:

A List of related parties:

i) Holding company:

Alivira Animal Health Limited, Ireland
 Alivira Animal Health Limited, India (Holding company of Alivira Animal Health Limited, Ireland)
 Sequent Scientific Limited, India (Ultimate Holding Company)

ii) Fellow subsidiary:

Fendigo BV
 Laboratorios Karizoo S.A

iii) Key Management Personnel

Mats Carlsson (Upto 16th August 2018)
 Bernard Bradfer

A. Transaction during the period

Nature of Transactions	Holding Company		Key Management Personnel		Fellow Subsidiary	
	Year ended 31 Mar 2019	Year ended 31 Mar 2018	Year ended 31 Mar 2019	Year ended 31 Mar 2018	Year ended 31 Mar 2019	Year ended 31 Mar 2018
(i) Sale of material/services Fendigo BV Laboratorios Karizoo S.A					9,71,267 -	9,64,058 1,332
(ii) Commission paid Fendigo BV					6,62,215	6,84,784
(iii) Professional/ Support Charges Alivira Animal Health Limited, India	-	1,85,000				
(iv) Managerial remuneration Mats Carlsson Bernard Bradfer			55,386 2,10,467	1,50,000 1,50,000		
(v) Interest received Alivira Animal Health Limited, Ireland	12,743	13,362				
(vi) Dividend Given Alivira Animal Health Limited, Ireland	1,85,000	3,40,000				
(v) Purchase of Goods Laboratorios Karizoo S.A					2,19,206	1,35,520

B. Balance as at balance sheet date:

Nature of Transactions	Holding Company		Key Management Personnel		Fellow Subsidiary	
	As at 31 March 2019	As at 31 March 2018	As at 31 March 2019	As at 31 March 2018	As at 31 March 2019	As at 31 March 2018
(i) Trade Receivable Fendigo BV Alivira Animal Health Limited, Ireland					93,748 -	76,465 5,488
(ii) Trade Payable Fendigo BV Laboratorios Karizoo S.A Alivira Animal Health Limited, India		1,85,000			68,396 41,300	82,144 60,744
(iii) Loan Outstanding Alivira Animal Health Limited, Ireland	5,00,000	5,00,000				
(iv) Other Receivables Alivira Animal Health Limited, Ireland	3,317	5,488				



FENDIGO SA**Notes to the financial statements for the year ended 31 March, 2019****Amounts in Euros (€) unless otherwise stated****27 Earnings per share**

Particulars	Year ended 31 Mar 2019	Year ended 31 Mar 2018
Net profit / (loss) for the year as per statement of profit and loss	3,84,455	3,20,124
Weighted average number of equity shares	6,250	6,250
Earnings / (Loss) per share - Basic	61.51	51.22
Earnings / (Loss) per share - Diluted	61.51	51.22

28 Contingent liabilities and commitments

There are no contingent liability and commitments as at 31 March 2019 (As on 31 March 2018 - Nil)

29 Segment information

Segments have been identified taking into account the nature of Operations, the differing risks and returns, the organisational structure and the internal reporting system.

Primary segment: Business segment

The Company is mainly engaged in the business of trading and marketing of Pharmaceutical products. Considering the nature of business and financial reporting of the Company, the Company has only one business segment viz; Pharmaceuticals as primary reportable segment. All the activities of the Company are in Europe.

As per our report of event date
For **M O J & ASSOCIATES**
Chartered Accountants
ICAI FRN: 015425S


Avneep Mehta
Partner
Membership no. 225441



Place: Bengaluru
Date: May 13, 2019

**FOR AND ON BEHALF OF THE
BOARD OF DIRECTORS**


Ashish Kakabalia
Director



Place: Thane
Date: May 13, 2019